🧾 What This Document Is

This is an FAQ document from Apellis Pharmaceuticals for its employees. It’s part of the official SEC filings related to the company's acquisition. Its purpose is to clearly explain the deal's details and directly answer the most pressing questions people inside the company have, from their stock options to their job security.

🤝 The Deal: Biogen Buys Apellis

Biogen, a large biotech company, is buying Apellis in an all-cash deal.

👉 In simple terms: Think of it like one company buying another at a set price. Here, Biogen is paying $41 per share for every Apellis stock share. The total deal is worth about $5.6 billion.

• Why it matters: This price represents a premium over the trading price, rewarding Apellis shareholders. The deal values Apellis based on its two key drugs, SYFOVRE (for eye disease) and EMPAVELI (for rare diseases).

💰 The Extra Payout: Contingent Value Rights (CVRs)

This is a crucial, extra piece of the deal that adds potential future value.

👉 How it works: Alongside the $41 cash, shareholders get one "Contingent Value Right" (CVR) per share. This CVR is like a lottery ticket for future cash if the drug SYFOVRE hits big sales targets.

• The Payout Scale: If SYFOVRE's annual sales hit $1.5B (2027-2030), you get $2 per CVR. If it hits $2B (2027-2030), you get another $2. If it misses those years but finally hits $2B in 2031, you get a $4 payment.

👥 What Happens to Employees & Their Equity

This section directly addresses employee concerns about their compensation, jobs, and unvested stock.

• Vested Shares/Options: You get $41 cash per share. For vested options "in the money" (strike price < $41), you get the cash difference plus a CVR.
• Unvested RSUs/Options: These convert into a "restricted cash award" based on the $41 price. This cash is paid out on your original vesting schedule, and you also get CVRs that vest on that same schedule.
• Job Security & Severance: No decisions yet. If let go without cause within 12 months of closing, you get severance based on your role and tenure (e.g., Managers get 7 weeks base salary + 2 weeks per year of service, max 26 weeks). Your health benefits (COBRA) are covered during this severance period.

📅 Timeline and Next Steps

The deal is announced but not finished. There's a waiting period for approvals.

• Expected Close: Q2 2026. It needs regulatory approval and shareholders to tender a majority of their shares.
• Business as Usual: Until it closes, Apellis and Biogen operate separately. Employees are told to continue their current work and not start integration planning themselves.
• Integration: A joint team will form soon to plan how the companies will merge.

⚖️ Big Picture: Strengths & Risks

👍 Strengths (Why the Deal Makes Sense):

• Strategic Fit: Biogen gets a stronger portfolio in immunology, rare disease, and nephrology (kidney diseases) via Apellis's drugs.
• Validation: The high price tag validates Apellis's science and its team's work.
• Scale: Apellis's drugs can potentially reach more patients faster with Biogen's global resources.

⚠️ Risks (What Could Go Wrong):

• Deal Collapse: The deal could fail if regulators block it or shareholders don't approve.
• Integration Challenges: Merging large companies is complex and can lead to cultural clashes and operational disruptions.
• CVR Uncertainty: The extra CVR payments are far from guaranteed and depend entirely on future drug sales performance.

🔮 What's Next for the Company

Focus remains on execution until the deal closes. The company's stated priorities are:

1. Expanding use of SYFOVRE for Geographic Atrophy (GA).
2. Continuing the strong launch of EMPAVELI in new indications (C3G and primary IC-MPGN).
3. Running clinical trials and advancing its drug pipeline.

🧠 The Analogy

This acquisition is like a talented, successful chef (Apellis) being bought out by a giant restaurant chain (Biogen). The chef gets a guaranteed $41 for the restaurant today, plus a royalty slip (the CVR) that pays extra if their signature dish (SYFOVRE) becomes a mega-bestseller in the coming years. The restaurant staff (employees) get paid out for their shares, and the chain promises to keep their pay the same for at least a year, though they might eventually work in a new kitchen.

🧩 Final Takeaway

Apellis shareholders are getting a $5.6 billion all-cash buyout at $41 per share, plus a potential extra payout tied to future sales of their key drug. Employees face a period of uncertainty but have clear, temporary protections on pay and severance if the deal closes and they are let go.